Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer


Cinieri S., Chan A., Altundag K., Vandebroek A., Tubiana-Mathieu N., Barnadas A., ...More

CLINICAL BREAST CANCER, vol.17, no.2, pp.91-99, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 2
  • Publication Date: 2017
  • Doi Number: 10.1016/j.clbc.2016.06.014
  • Journal Name: CLINICAL BREAST CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.91-99
  • Keywords: Capecitabine, Combination chemotherapy, Oral chemotherapy, Oral vinorelbine, Taxane doublet, CAPECITABINE PLUS DOCETAXEL, ANTHRACYCLINE-PRETREATED PATIENTS, INTERNATIONAL CONSENSUS GUIDELINES, NON-INFERIORITY, OPEN-LABEL, VINORELBINE, GEMCITABINE, COMBINATION, PACLITAXEL, BEVACIZUMAB
  • Gazi University Affiliated: No

Abstract

This randomized phase II trial compared first-line all-oral vinorelbine/capecitabine, gemcitabine/paclitaxel, and gemcitabine/docetaxel for HER2-negative metastatic breast cancer. Disease control rates (primary end point) were 73%, 78%, and 80%, respectively; median progression-free survival was 7.6, 9.0, and 11.4 months; median overall survival was 30 to 31 months with all regimens. All-oral vinorelbine/capecitabine is an active first-line regimen, and avoids alopecia and frequent intravenous administrations.